Balchem Corporation (BCPC) Spending and interest coverage
- R&D / revenue · 12 months: Value 1.84%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.81%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1.84% | Research and development expense / revenue. Period ending 2026-06-30. $19.96M ÷ $1.09B × 100 ≈ 1.84% |
| Stock-based compensation / revenue · 12 months | 1.81% | Share-based compensation / revenue. Period ending 2026-06-30. $19.69M ÷ $1.09B × 100 ≈ 1.81% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 19.96M USD | Research and Development Expense |
| Revenue | 1.09B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 19.69M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 221.72M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.96M | $1.09B | $19.69M | $221.72M | (m) | 1.84% | 1.81% | (m) | (m) |
| 2026-03-31 | $19.73M | $1.06B | $19.60M | $213.94M | (m) | 1.87% | 1.85% | (m) | (m) |
| 2025-12-31 | $18.51M | $1.04B | $18.06M | $209.33M | (m) | 1.78% | 1.74% | (m) | (m) |
| 2025-09-30 | $17.97M | $1.01B | $18.19M | $204.48M | (m) | 1.77% | 1.79% | (m) | (m) |
| 2025-06-30 | $17.80M | $985.93M | $17.69M | $197.89M | (m) | 1.81% | 1.79% | (m) | (m) |
| 2025-03-31 | $17.36M | $964.54M | $15.73M | $192.25M | (m) | 1.80% | 1.63% | (m) | (m) |
| 2024-12-31 | $16.79M | $953.68M | $16.68M | $182.91M | (m) | 1.76% | 1.75% | (m) | (m) |
| 2024-09-30 | $16.22M | $942.38M | $16.57M | $173.80M | (m) | 1.72% | 1.76% | (m) | (m) |
| 2024-06-30 | $15.76M | $932.39M | $16.17M | $169.42M | (m) | 1.69% | 1.73% | (m) | (m) |
| 2024-03-31 | $15.70M | $929.56M | $16.03M | $166.46M | (m) | 1.69% | 1.72% | (m) | (m) |
| 2023-12-31 | $15.05M | $922.44M | $16.05M | $159.19M | (m) | 1.63% | 1.74% | (m) | (m) |
| 2023-09-30 | $14.15M | $926.27M | $15.65M | $154.16M | (m) | 1.53% | 1.69% | (m) | (m) |
| 2023-06-30 | $13.28M | $940.59M | $14.85M | $144.17M | (m) | 1.41% | 1.58% | (m) | (m) |
| 2023-03-31 | $12.41M | $946.03M | $14.92M | $141.26M | (m) | 1.31% | 1.58% | (m) | (m) |
| 2022-12-31 | $12.19M | $942.36M | $13.22M | $145.19M | (m) | 1.29% | 1.40% | (m) | (m) |
| 2022-09-30 | $13.87M | $922.96M | $11.83M | $145.70M | (m) | 1.50% | 1.28% | (m) | (m) |
| 2022-06-30 | $14.03M | $876.56M | $11.78M | $144.59M | (m) | 1.60% | 1.34% | (m) | (m) |
| 2022-03-31 | $14.01M | $842.23M | $11.26M | $135.26M | (m) | 1.66% | 1.34% | (m) | (m) |
| 2021-12-31 | $13.52M | $799.02M | $10.80M | $127.50M | (m) | 1.69% | 1.35% | (m) | (m) |
| 2021-09-30 | $11.18M | $766.60M | $10.36M | $122.61M | (m) | 1.46% | 1.35% | (m) | (m) |
| 2021-06-30 | $10.71M | $743.87M | $9.72M | $119.12M | (m) | 1.44% | 1.31% | (m) | (m) |
| 2021-03-31 | $10.38M | $714.86M | $8.74M | $115.44M | (m) | 1.45% | 1.22% | (m) | (m) |
| 2020-12-31 | $10.33M | $703.64M | $8.30M | $111.15M | (m) | 1.47% | 1.18% | (m) | (m) |
| 2020-09-30 | $10.89M | $689.46M | $8.63M | $105.86M | (m) | 1.58% | 1.25% | (m) | (m) |
| 2020-06-30 | $10.90M | $672.91M | $8.47M | $102.87M | (m) | 1.62% | 1.26% | (m) | (m) |
| 2020-03-31 | $11.18M | $661.11M | $8.15M | $102.35M | (m) | 1.69% | 1.23% | (m) | (m) |
| 2019-12-31 | $11.38M | $643.71M | $7.60M | $102.55M | (m) | 1.77% | 1.18% | (m) | (m) |
| 2019-09-30 | $11.70M | $640.72M | $6.92M | $106.80M | (m) | 1.83% | 1.08% | (m) | (m) |
| 2019-06-30 | $11.54M | $637.16M | $6.58M | $106.29M | (m) | 1.81% | 1.03% | (m) | (m) |
| 2019-03-31 | $11.92M | $639.30M | $6.25M | $106.99M | (m) | 1.86% | 0.98% | (m) | (m) |
| 2018-12-31 | $11.59M | $643.68M | $6.41M | $107.75M | (m) | 1.80% | 1.00% | (m) | (m) |
| 2018-09-30 | $10.84M | $639.40M | $7.12M | $107.16M | $7.79M | 1.69% | 1.11% | 13.76× | Reported |
| 2018-06-30 | $11.01M | $635.08M | $6.84M | $104.75M | $8.00M | 1.73% | 1.08% | 13.10× | Reported |
| 2018-03-31 | $10.06M | $618.47M | $6.22M | $101.96M | $7.62M | 1.63% | 1.01% | 13.38× | Reported |
| 2017-12-31 | $9.30M | $594.79M | $6.26M | $97.25M | $7.54M | 1.56% | 1.05% | 12.89× | Reported |
| 2017-09-30 | $8.59M | $576.29M | $5.73M | $95.18M | $7.43M | 1.49% | 0.99% | 12.81× | Reported |
| 2017-06-30 | $7.56M | $564.08M | $5.96M | $95.07M | $7.21M | 1.34% | 1.06% | 13.19× | Reported |
| 2017-03-31 | $7.20M | $555.79M | $6.67M | $93.57M | $7.22M | 1.30% | 1.20% | 12.96× | Reported |
| 2016-12-31 | $7.33M | $553.20M | $7.02M | $90.84M | $7.26M | 1.32% | 1.27% | 12.50× | Reported |
| 2016-09-30 | $7.08M | $545.17M | $6.82M | $88.47M | $7.04M | 1.30% | 1.25% | 12.57× | Reported |
| 2016-06-30 | $6.91M | $546.79M | $8.09M | $88.44M | $6.87M | 1.26% | 1.48% | 12.88× | Reported |
| 2016-03-31 | $6.48M | $542.77M | $7.85M | $88.89M | $6.55M | 1.19% | 1.45% | 13.56× | Reported |
| 2015-12-31 | $5.99M | $552.49M | $6.83M | $93.96M | $6.59M | 1.08% | 1.24% | 14.25× | Reported |
| 2015-09-30 | $5.92M | $582.43M | $6.76M | $98.73M | $6.87M | 1.02% | 1.16% | 14.37× | Reported |
| 2015-06-30 | $5.86M | $602.79M | $4.89M | $101.09M | $7.30M | 0.97% | 0.81% | 13.84× | Reported |
| 2015-03-31 | $5.49M | $600.25M | $4.74M | $93.83M | $7.03M | 0.91% | 0.79% | 13.36× | Reported |
| 2014-12-31 | $4.81M | $541.38M | $4.56M | $82.14M | $5.14M | 0.89% | 0.84% | 15.97× | Reported |
| 2014-09-30 | $4.30M | $460.35M | $4.38M | $71.29M | $3.39M | 0.93% | 0.95% | 21.05× | Reported |
| 2014-06-30 | $3.73M | $387.45M | $4.18M | $62.98M | $1.34M | 0.96% | 1.08% | 47.11× | Reported |
| 2014-03-31 | $3.56M | $338.52M | $3.73M | $63.09M | $24.00K | 1.05% | 1.10% | 2628.83× | Reported |
| 2013-12-31 | $3.62M | $337.17M | $3.82M | $65.60M | $24.00K | 1.07% | 1.13% | 2733.42× | Reported |
| 2013-09-30 | $3.46M | $335.60M | $3.86M | $64.49M | $7.00K | 1.03% | 1.15% | 9213.43× | Reported |
| 2013-06-30 | $3.48M | $323.12M | $3.94M | $63.76M | $7.00K | 1.08% | 1.22% | 9108.29× | Reported |
| 2013-03-31 | $3.48M | $318.84M | $4.01M | $61.97M | $8.00K | 1.09% | 1.26% | 7745.88× | Reported |
| 2012-12-31 | $3.42M | $310.39M | $3.91M | $59.78M | $10.00K | 1.10% | 1.26% | 5977.70× | Reported |
| 2012-09-30 | $3.25M | $300.07M | $3.79M | $58.43M | $20.00K | 1.08% | 1.26% | 2921.65× | Reported |
| 2012-06-30 | $3.00M | $299.39M | $3.70M | $57.37M | $50.00K | 1.00% | 1.24% | 1147.36× | Reported |
| 2012-03-31 | $2.79M | $295.06M | $3.64M | $56.60M | $69.00K | 0.95% | 1.23% | 820.32× | Reported |
| 2011-12-31 | $2.89M | $291.87M | $3.69M | $56.23M | $84.00K | 0.99% | 1.26% | 669.35× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $268.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $3.19M | $255.07M | $3.99M | $49.77M | $90.00K | 1.25% | 1.57% | 553.00× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $3.30M | $219.44M | $3.08M | $40.66M | $209.00K | 1.50% | 1.40% | 194.54× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perimeter Solutions, Inc. (PRM) | $4.593B | -17.21 | |
| Ingevity Corp (NGVT) | United States | $2.468B | 47.72 |
| INNOSPEC INC. (IOSP) | United States | $2.380B | 16.37 |
| Chemours Co (CC) | United States | $2.136B | -10.64 |
| OLIN Corp (OLN) | United States | $1.852B | -11.54 |
| Solstice Advanced Materials Inc. (SOLS) | United States | $8.905B | 67.02 |
| Huntsman CORP (HUN) | United States | $1.540B | -6.95 |
| FMC CORP (FMC) | United States | $1.201B | -0.52 |
| Ecovyst Inc. (ECVT) | United States | $1.110B | -22.22 |
| ASCENT INDUSTRIES CO. (ACNT) | United States | $0.132B | -30.55 |